Aosaikang Pharmaceutical Applies For Type 3.1 Hematopoietic Drug Promacta APIs and Tablets
This article was originally published in PharmAsia News
Executive Summary
China FDA has accepted Aosaikang Pharmaceutical’s application for a new Type 3.1 hematopoietic drug, Promacta (eltrombopag) APIs and tablets.